The subcutaneous dose applied in the STEP studies (2.4 mg) is higher than that administered in the SUSTAIN studies (0.5 mg to 1.0 mg)
The trade-off is regulatory: compounded medications are not FDA-approved, which is why provider review and licensed-pharmacy sourcing matter
Tesamorelin holds FDA approval for HIV-associated lipodystrophy based on two Phase 3 RCTs (Falutz et al., 2007 and 2010) showing roughly 15 to 18 percent visceral adipose tissue reduction versus placebo at 26 weeks
Long-term use requires ongoing medical supervision to monitor for side effects, adjust dosing, and ensure the treatment continues to provide benefit
I break down the common symptoms I hear about most (fatigue, brain fog, pain, neurological issues), related conditions (autoimmune disease, chronic fatigue, implant-associated cancers), and the biology behind it: siloxane (silicone) leaching, how bacterial biofilms or mold can play a role, and how the fibrous capsule surrounding implants can trap toxins and sometimes become the site of serious cancers
Its most commonly found in African Americans, Hispanics/Latinos, and Asians, while its less common in people of European descent
